SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

Lantern Pharma gets USPTO Notice of Allowance for LP-284 patent

Lantern Pharma said the USPTO issued a Notice of Allowance for its LP—284 treatment patent application for aggressive B—cell lymphomas.

LTRN

Lantern Pharma Inc. (NASDAQ: LTRN) said the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application N…

Related stories